In CRC, CD133 silencing partially inhibits proliferation, clonogenic capacity, migration, cell invasion, and resistance by reducing glucose uptake due to reduced glucose transporter 1 expression [72,73] (Figure 3). The gene discussed is PROM1; the disease is colorectal carcinoma.